NEWS - Jul 27, 2021 Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential Read more
NEWS - Jul 20, 2021 Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC Read more
NEWS - Jun 15, 2021 Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting Read more
NEWS - Jun 7, 2021 Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference Read more
NEWS - Jun 1, 2021 Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference Read more
NEWS - May 26, 2021 Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting Read more
NEWS - May 12, 2021 Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results Read more
NEWS - May 6, 2021 Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021 Read more
NEWS - May 1, 2021 Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021 Read more
NEWS - Apr 29, 2021 Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting Read more
